



**Universiteit
Leiden**
The Netherlands

Discovering biomarkers and druggable targets in uveal melanoma

Wierenga, A.P.A.

Citation

Wierenga, A. P. A. (2026, June 24). *Discovering biomarkers and druggable targets in uveal melanoma*. Retrieved from <https://hdl.handle.net/1887/4306948>


Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4306948>

Note: To cite this publication please use the final published version (if applicable).

Appendices



List of publications

Curriculum vitae

Summary in Dutch

Acknowledgements

List of publications

1. Iris Colour and the Risk of Developing Uveal Melanoma.
Houtzagers LE, **Wierenga APA**, Ruys AAM, Luyten GPM, Jager MJ.
Int J Mol Sci. 2020 Sep 28;21(19):7172. doi: 10.3390/ijms21197172.
PMID: 32998469 .Review.
2. HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.
Souri Z, **Wierenga APA**, Mulder A, Jochemsen AG, Jager MJ.
Cancers (Basel). 2019 Aug 7;11(8):1132. doi: 10.3390/cancers11081132.
PMID: 31394860 .Review.
3. LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma.
Souri Z, **Wierenga APA**, Kroes WGM, van der Velden PA, Verdijk RM, Eikmans M, Luyten GPM, Jager MJ.
Cancers (Basel). 2021 Sep 3;13(17):4445. doi: 10.3390/cancers13174445.
PMID: 34503258 .
4. Chromosome 3 and 8q Aberrations in Uveal Melanoma Show Greater Impact on Survival in Patients with Light Iris versus Dark Iris Color.
Wierenga APA, Brouwer NJ, Gelmi MC, Verdijk RM, Stern MH, Bas Z, Malkani K, van Duinen SG, Ganguly A, Kroes WGM, Marinkovic M, Luyten GPM, Shields CL, Jager MJ.
Ophthalmology. 2022 Apr;129(4):421-430. doi: 10.1016/j.ophtha.2021.11.011.
Epub 2021 Nov 13.
PMID: 34780841
5. Increased Histological Tumor Pigmentation in Uveal Melanoma Is Related to Eye Color and Loss of Chromosome 3/BAP1.
Gelmi MC, **Wierenga APA**, Kroes WGM, van Duinen SG, Karuntu JS, Marinkovic M, Bleeker JC, Luyten GPM, Vu THK, Verdijk RM, Jager MJ.
Ophthalmol Sci. 2023 Mar 11;3(3):100297. doi: 10.1016/j.xops.2023.100297.
eCollection 2023 Sep.
PMID: 37193315 .
6. In Uveal Melanoma, Angiopoietin-2 but Not Angiopoietin-1 Is Increased in High-Risk Tumors, Providing a Potential Druggable Target.
Ten Voorde AMW, **Wierenga APA**, Nell RJ, van der Velden PA, Luyten GPM, Verdijk RM, Jager MJ.
Cancers (Basel). 2021 Aug 7;13(16):3986. doi: 10.3390/cancers13163986.
PMID: 34439141 .

7. Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?
van Weeghel C, **Wierenga APA**, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.
Cancers (Basel). 2019 Aug 7;11(8):1127. doi: 10.3390/cancers11081127.
PMID: 31394807 .
8. Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution.
Brouwer NJ, Gezgin G, **Wierenga APA**, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM, Jager MJ.
Cancers (Basel). 2019 Jul 13;11(7):979. doi: 10.3390/cancers11070979.
PMID: 31337000 .
9. Expression of HDACs 1, 3 and 8 Is Upregulated in the Presence of Infiltrating Lymphocytes in Uveal Melanoma.
Souri Z, Jochemsen AG, **Wierenga APA**, Kroes WGM, Verdijk RM, van der Velden PA, Luyten GPM, Jager MJ.
Cancers (Basel). 2021 Aug 18;13(16):4146. doi: 10.3390/cancers13164146.
PMID: 34439300 .
10. MiRNAs Correlate with HLA Expression in Uveal Melanoma: Both Up- and Downregulation Are Related to Monosomy 3.
Souri Z, **Wierenga APA**, Kiliç E, Brosens E, Böhringer S, Kroes WGM, Verdijk RM, van der Velden PA, Luyten GPM, Jager MJ.
Cancers (Basel). 2021 Aug 10;13(16):4020. doi: 10.3390/cancers13164020.
PMID: 34439175 .
11. Loss of BAP1 Is Associated with Upregulation of the NFκB Pathway and Increased HLA Class I Expression in Uveal Melanoma.
Souri Z, **Wierenga APA**, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.
Cancers (Basel). 2019 Aug 2;11(8):1102. doi: 10.3390/cancers11081102.
PMID: 31382450 .
12. Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time.
Roelofsen CDM, **Wierenga APA**, van Duinen S, Verdijk RM, Bleeker J, Marinkovic M, Luyten GPM, Jager MJ.
Ocul Oncol Pathol. 2021 Mar;7(2):133-141. doi: 10.1159/000509918. Epub 2020 Dec 15.
PMID: 33981696.
13. Ischemia Is Related to Tumour Genetics in Uveal Melanoma.
Brouwer NJ, **Wierenga APA**, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM, Jager MJ.
Cancers (Basel). 2019 Jul 18;11(7):1004. doi: 10.3390/cancers11071004.
PMID: 31323773 .

14. HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma.
Souri Z, Jochemsen AG, Versluis M, **Wierenga APA**, Nemati F, van der Velden PA, Kroes WGM, Verdijk RM, Luyten GPM, Jager MJ.
Cancers (Basel). 2020 Dec 9;12(12):3690. doi: 10.3390/cancers12123690.
PMID: 33316946 .
15. Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery.
Yin J, Zhao G, Kalirai H, Coupland SE, Jochemsen AG, Forn-Cuní G, **Wierenga APA**, Jager MJ, Snaar-Jagalska BE, Groenewoud A.
Pharmaceuticals (Basel). 2023 Apr 15;16(4):598. doi: 10.3390/ph16040598.
PMID: 37111355 .
16. Aqueous Humor Biomarkers Identify Three Prognostic Groups in Uveal Melanoma.
Wierenga APA, Cao J, Mouthaan H, van Weeghel C, Verdijk RM, van Duinen SG, Kroes WGM, Dogrusöz M, Marinkovic M, van der Burg SSH, Luyten GPM, Jager MJ.
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4740-4747. doi: 10.1167/iovs.19-28309.
PMID: 31731294
17. Soluble HLA in the Aqueous Humour of Uveal Melanoma Is Associated with Unfavourable Tumour Characteristics.
Wierenga APA, Gezgin G, van Beelen E, Eikmans M, Spruyt-Gerritse M, Brouwer NJ, Versluis M, Verdijk RM, van Duinen SG, Marinkovic M, Luyten GPM, Jager MJ.
Cancers (Basel). 2019 Aug 18;11(8):1202. doi: 10.3390/cancers11081202.
PMID: 31426578 .
18. Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma
Wierenga APA, Cao J, Luyten GPM, Jager MJ
Int Ophthalmol Clin 2019 Vol. 59 Issue 2 Pages 53-63
Accession Number: 30908279 DOI: 10.1097/iiio.0000000000000263
PMID: 30908279
19. Survival in Patients with Uveal Melanoma Is Linked to Genetic Variation at HERC2 Single Nucleotide Polymorphism rs12913832.
Gelmi MC, Houtzaggers LE, **Wierenga APA**, Versluis M, Heijmans BT, Luyten GPM, de Knijff P, Te Raa M, de Leeuw RH, Martine J Jager .
Ophthalmology. 2025 Mar;132(3):299-308. doi: 10.1016/j.ophtha.2024.09.001.
Epub2024 Sep 7
PMID: 39245076.

Curriculum Vitae

Annemijn was born on the 14th of December 1989 in Nieuwegein, The Netherlands. She grew up in IJsselstein and after primary school continued her secondary education at the Anna van Rijn College.

She followed Higher Bilingual Education, including exchanges with high schools in Canterbury and Oxford as well as an internship, with the aim of gaining international working experience, at FlatIron Construction Corporation headquarters in San Diego, California, United States of America. She received her International Baccalaureate English higher level from the IB world school and graduated top of her class.

She continued her education and studied Medicine at the University of Leiden, where she continued her international interests. During the summer of 2011 she completed an extracurricular clinical internship at the Department of Internal Medicine in Assiut Egypt. In 2012, she co-organized a study-trip to Jerusalem and Tel-Aviv in Israel, as secretary and deputy-chairman of the International Medical Study Travel Committee of the M.F.L.S. In 2012 she did her scientific research internship in urogynecology, under the supervision of dr. Christopher Maher at The Wesley Hospital Brisbane, The Royal Brisbane and Women's hospital and the Mater Private Hospital in Brisbane, Australia. During her master studies in Medicine she took courses of the minor Business Administration at the Faculty of Law at Leiden University. Arising from this she pursued an extra-curricular Turnaround Management internship at the Koninklijk Instituut voor de Tropen, in Amsterdam, The Netherlands.

As part of her elective internships, she conducted a three-month internship with The United Nations, at the World Health Organization, in Copenhagen, Denmark.

She fulfilled her senior internship at the Department of Ophthalmology at the Leiden University Medical Center (LUMC) and received her Master's degree in 2015. She subsequently started her PhD under supervision of Professor Dr. Martine J. Jager.

She went on a Short Term Scientific Mission (STSM) of three weeks at the Center for Cell Therapy and Regenerative Medicine in Antwerp Belgium where she studied how to culture corneal endothelial, stromal and epithelial cells. Additionally, she attended two Summer schools on corneal pathology and regeneration, in Varna Bulgaria (2016) and in Linköping, Sweden (2017).

In 2017 she started a Fellowship at ARVO in Science Communication as part of the Advocacy and Outreach Expert Development Program, including a visit to Capitol Hill, meeting with members from the House of Representatives and policy makers to advocate for federal funding for the National Institutes of Health (NIH) and National Eye Institute (NEI).

Arising from this, she organized a patient information evening at the LUMC on Uveal Melanoma.

In 2019 she followed the program “Doctor meets Director”, of Medical Business Education, gaining insight into medical and hospital management.

Annemijn has delivered oral presentations at the OOG Spring Meeting in February 2017, at the DOPS meetings in 2017, 2018 and 2019, at the Ocular Oncogenesis and Oncology Conference, Champalimaud, Lisbon, Portugal and at UM CURE meetings as well as at the International Society of Ocular Oncology 2023. She presented posters at the ARVO in 2017 and 2019 and she was moderator of the oncology paper session at ARVO 2019. She further attended and presented at National meetings, including ARVO-Ned and NOG.

In 2020, she started her residency in Ophthalmology at the LUMC under supervision of Professor Dr. Gregorius P.M. Luyten and Professor Dr. Nicoline Schalijs-Delfos. During this time she became a mother to Lode and Theijmen.